Member Directory

Chair: Charles Flexner

Objectives:

  • Create the scientific and programmatic agenda of LEAP to ensure a balanced and objective resource for those engaged in developing LA/ER agents for treatment and prevention of HIV, TB, and Hepatitis B & C.
  • Bring a broad representation including academic experts in LA/ER therapeutic drug development, community representatives, and non-governmental organizations (NGO’s) with an interest in supporting this field.
  • Serve as an honest broker to bridge gaps between academia, regulatory agencies, the pharmaceutical industry, and the community.

Charles W. Flexner, MD, is the Principal Investigator of the Long Acting/Extended Release Antiretroviral Resource Program (LEAP). He is Professor of Medicine in the Divisions of Clinical Pharmacology and Infectious Diseases, and Professor of Pharmacology and Molecular Sciences in the Johns Hopkins University School of Medicine. He is also Professor of International Health in the Johns Hopkins University Bloomberg School of Public Health.

Dr. Abrams is a Professor of Epidemiology and Pediatrics at Columbia University with over 35 years of experience in the prevention and treatment of HIV infection and associated infectious diseases in pregnant women, children, and their families. As the Senior Director for Research at ICAP, she leads ICAP’s large research agenda and is responsible for the development of technical assistance and service programs for pediatric and perinatal prevention initiatives for ICAP programs in sub-Saharan Africa and Asia.

Terrence F. Blaschke, MD, is Professor of Medicine and Molecular Pharmacology (Emeritus) at Stanford University, Adjunct Professor of Bioengineering and Therapeutic Sciences at UCSF and Adjunct Professor of Medicine at Indiana University. He joined the faculty at Stanford University School of Medicine in 1974. Dr. Blaschke was a member of the AIDS Clinical Trials Group and served as chair of the Pharmacology Committee.

Dr. Bollinger is Founding Director of the Center for Clinical Global Health Education (CCGHE) and Professor of Infectious Diseases at the Johns Hopkins University (JHU) School of Medicine. He holds joint appointments in international health at the Johns Hopkins (JH) Bloomberg School of Public Health, and in community public health at the JH School of Nursing.

.

Paul is accountable for developing and transferring for manufacture better and less expensive chemistries, formulations, and fixed-dose combination products for adults and children; supporting treatment optimization through the development, regulatory filing, and quality assessment of new products, diagnostics, and devices; providing clinical guidance on managing diseases and transitioning to new treatment paradigms;

Dr. Rodney JY Ho is a distinguished professor of pharmaceutics (SOP), adjunct professor of bioengineering (SOM) and is an inaugural presidential entrepreneurial fellow of the University of Washington. He is also a member of Fred Hutchinson Cancer Research Center. He is the Founder and Executive Director of the Center for WE-REACH, a National Research Acceleration and Commercialization Hub. His research encompasses basic and translational sciences for improving the therapeutic efficacy and safety of viral and cancer drugs, diagnostic agents and vaccines. 

Jeffrey M. Jacobson, MD is Professor of Medicine and Neuroscience and Co-Director, Center of Translational AIDS Research Lewis Katz School of Medicine at Temple University. He has extensive experience in the care and investigative study of HIV-infected patients. His particular focus of research has been on the immunology and immunopathogenesis of HIV-1 infection, including vaccine, gene and other immune-based therapies, as well as monoclonal antibody development.

In 1996, Andy began volunteering at Christie’s Place, an agency serving women, children, and families impacted by HIV/AIDS in San Diego.  This led to an interest in HIV and other types of medical research. His past and current work has included treatment and research education, support group facilitation, and patient advocacy.

Daniel R. Kuritzkes, MD received his BS and MS degrees in Molecular Biophysics and Biochemistry from Yale University, and his MD from Harvard Medical School. He completed his clinical and research training in internal medicine and infectious diseases at Massachusetts General Hospital and was a visiting scientist at the Whitehead Institute for Biomedical Research before joining the faculty at the University of Colorado Health Sciences Center. 

Ms. McKenzie-White is Managing Director and Senior Program Officer at the Center for Clinical Global Health Education. She has more than 20 years of experience in program leadership, web development, health education, and research. Since joining CCGHE in 2006, her efforts have focused on distance learning and capacity-building. Her work has contributed to numerous peer-reviewed publications on leveraging technology to facilitate clinical global health education and optimize healthcare delivery.

Mark Mirochnick, M.D. is Professor of Pediatrics and a member of the Division of Neonatology at Boston University School of Medicine/Boston Medical Center. He has extensive experience in clinical trials investigating the clinical pharmacology of antiretrovirals and TB drugs in neonates, infants, children and pregnant women.

Andrew Owen is a Professor in the Department of Molecular and Clinical Pharmacology at the University of Liverpool. He is also affiliated to the MRC Centre for Drug Safety Science and the Wolfson Centre for Personalised Medicine. He is Chair of the British Society for Nanomedicine, a fellow of the Royal Society of Biology, and a member of the steering committee for the Academy of Pharmaceutical Sciences Nanomedicines Focus Group. 

Kimberly Struble, PharmD, is a Senior Clinical Team Leader in the Division of Antiviral Products at the Food and Drug Administration. She provides expertise in all phases of antiviral clinical drug development and leads a team responsible for the development of new products for the treatment and prevention of HIV infection, hepatitis B and C, influenza, various herpes infections, and other emerging viral infections. 

Susan Swindells is a Professor of Internal Medicine in the Section of Infectious Diseases at the University of Nebraska Medical Center, USA.  A native of England, Dr. Swindells earned her medical degree from University College London in 1977, with postgraduate training in England and at the University of Washington in Seattle.  She has been involved in HIV care since 1984. 

David Thomas is Director of Infectious Diseases and the Stanhope Bayne-Jones Professor of Medicine at the Johns Hopkins School of Medicine. His research is focused on hepatitis viruses, especially interactions between HIV and viral hepatitis. Dr. Thomas has served the National Institutes of Health and leading professional societies and the associated biomedical journals in multiple leadership/editorial capacities.